DEF 14A: 180 Life Sciences Corp. Sets Date for 2024 Annual Stockholders Meeting, Outlines Key Proposals

180 Life Sciences Corp. announces its 2024 annual meeting of stockholders to address director elections, incentive plan amendments, executive compensation, and stock issuance approvals.

Summary

• 180 Life Sciences Corp. will hold its 2024 annual meeting of stockholders on December 27, 2024, at 1:00 p.m. Pacific Time, conducted virtually.
• Stockholders will vote on several proposals, including the election of three Class II directors, adoption of the Third Amendment to the 180 Life Sciences Corp. 2022 Omnibus Incentive Plan, and an advisory resolution on Named Executive Officer compensation.
• Additionally, stockholders will vote on proposals to approve the issuance of more than 20% of the company's common stock upon conversion of Series B Convertible Preferred Stock and exercise of outstanding warrants, both to comply with Nasdaq Listing Rules.
• The meeting will also include a vote to ratify the appointment of M&K CPAs, PLLC, as the company's independent auditors for the fiscal year ending December 31, 2024.
• The Board of Directors recommends voting for all director nominees and for all proposals.
• The record date for determining stockholders eligible to vote is October 31, 2024.
• The company's proxy materials and Annual Report on Form 10-K for the year ended December 31, 2023, are available online and upon request.

Sentiment

Score: 7

Explanation: The document is a standard proxy statement, presenting factual information and recommendations. The sentiment is neutral to slightly positive, reflecting the company's efforts to engage with stockholders and maintain regulatory compliance.

Positives

• The Board of Directors is actively seeking stockholder input on key governance and compensation matters.
• The company is taking steps to comply with Nasdaq Listing Rules, demonstrating a commitment to regulatory compliance.
• The availability of proxy materials online aims to reduce costs and environmental impact.

Risks

• Failure to approve the stock issuance proposals could impact the company's ability to comply with Nasdaq Listing Rules.
• The ongoing legal proceedings involving former executives and related parties could result in significant financial liabilities.
• The company's ability to achieve its performance goals and execute its strategies is subject to various risks and uncertainties, including the need for additional funding and changing government regulations.

Future Outlook

The document outlines proposals for future actions requiring stockholder approval, including stock issuances and incentive plan amendments, which are crucial for the company's strategic direction and compliance.

Management Comments

• Our Board of Directors encourages your participation in 180 Life Sciences Corp.'s electoral process and, to that end, solicits your proxy with respect to the matters described in the Notice of Meeting and the proxy statement.
• We look forward to seeing you on December 27, 2024.
• Your vote and participation in our governance is very important to us.

Industry Context

The proposals related to stock issuance and executive compensation are common practices for publicly traded companies to maintain competitiveness and incentivize performance within the biotechnology industry.

Comparison to Industry Standards

• The executive compensation structure, including salary, bonus, and equity awards, is typical for companies of similar size and stage in the biotechnology sector.
• The use of an omnibus incentive plan is a standard practice among publicly traded companies to attract, retain, and motivate employees and directors.
• The need for stockholder approval for stock issuances exceeding 20% is a common requirement under Nasdaq listing rules, ensuring shareholder oversight of significant corporate actions.
• Comparable companies such as BioAtla, Inc. (NASDAQ:BCAB) and Pasithea Therapeutics Corp. (NASDAQ:KTTA) also have similar corporate governance structures and compensation practices.

Management Changes

Corporate Governance

Legal Proceedings

• The Company initiated legal action in the Chancery Court of Delaware against Dr. Marlene Krauss, the Company’s former Chief Executive Officer and director (Dr. Krauss) and two of her affiliated companies, KBL IV Sponsor, LLC and KBL Healthcare Management, Inc. (collectively, the KBL Affiliates) for, among other things, engaging in unauthorized monetary transfers of the Company’s assets, non-disclosure of financial liabilities within the Company’s Consolidated Financial Statements, issuing shares of stock without proper authorization; and improperly allowing stockholder redemptions to take place.
• On August 19, 2021, Dr. Krauss initiated legal action in the Chancery Court of Delaware against the Company. The Complaint alleged that the Company is obligated to advance expenses including, attorneys fees, to Dr. Krauss for the costs of defending against an SEC investigation and Subpoenas, and that the Company is also required to reimburse Dr. Krauss for the costs of bringing this lawsuit against the Company.
• The Company commenced and filed an action against defendant Tyche Capital LLC (Tyche) in the Supreme Court of New York in the County of New York on April 15, 2021. In its Complaint, the Company alleged claims against Tyche arising out of Tyches breach of its written contractual obligations to the Company as set forth in a Guarantee and Commitment Agreement dated July 25, 2019, and a Term Sheet for KBL Business Combination With CannBioRex dated April 10, 2019 (collectively, the Subject Guarantee), and claimed that Tyches breach of the Subject Guarantee caused the Company damages in the amount of at least $6,776,686.
• The Company and two of its wholly-owned subsidiaries, Katexco Pharmaceuticals Corp. and CannBioRex Pharmaceuticals Corp. (collectively, the Company Plaintiffs), initiated legal action against Ronald Bauer and Samantha Bauer, as well as two of their companies, Theseus Capital Ltd. and Astatine Capital Ltd. (collectively, the Bauer Defendants), in the Supreme Court of British Columbia on February 25, 2022.
• On June 29, 2022, AmTrust International Underwriters DAC (AmTrust), which was the premerger directors and officers insurance policy underwriter for KBL, filed a declaratory relief action against the Company in the U.S. District Court for the Northern District of California (the Declaratory Relief Action) seeking a declaration that AmTrust is not obligated to reimburse the Company for fees advanced by the Company to Dr. Krauss and George Hornig under the directors and officers insurance policy.

Related Party Transactions

• On July 1, 2020, we entered into an amended agreement with ReFormation Pharmaceuticals, Corp. (ReFormation) and 360 Life Sciences Corp. (360), whereby 360 has entered into an agreement to acquire 100% ownership of ReFormation, on or before July 31, 2020 (Closing Date).
• On December 29, 2020, we received notice from Marlene Krauss, M.D., the former Chief Executive Officer and director of KBL, alleging the occurrence of an event of default of the terms of a certain promissory note in the amount of $371,178, dated March 15, 2019, evidencing amounts owed by us to KBL IV Sponsor LLC (of which Dr. Krauss serves as sole managing member), for failure to repay such note within five days of the release of funds from escrow in connection with the terms of a purchase agreement.
• During the year ended December 31, 2022, we incurred general and administrative expenses related parties of $5,612 compared to $462,580 incurred for the year ended December 31, 2021, representing a decrease of $456,968, or 99%.
• For the years ended December 31, 2023 and 2022, the Company recognized interest expense related parties associated with outstanding loans payable of $18,436 and $14,156, respectively.
• During the years ended December 31, 2023 and 2022, the Company recorded $0 and $1,508, respectively, of interest income related parties, which related to interest income on loans with officers and directors of the Company.
• Accrued expenses related parties were $0 and $188,159 as of December 31, 2023 and 2022, respectively, and consist of interest accrued on loans and convertible notes due to certain officers and directors of the Company, as well as deferred compensation for certain executives.
• During the year ended December 31, 2023, we incurred research and development expenses related parties of $480,777 compared to $240,731 incurred for the year ended December 31, 2022, representing an increase of $240,046 or 100%.

Stakeholder Impact

• Approval of the proposals will impact shareholders through potential dilution and changes in corporate governance.
• Executive officers are affected by the advisory vote on compensation and the potential changes to the incentive plan.
• Employees may be impacted by the changes to the incentive plan, which could affect their compensation and motivation.

Next Steps

• Mail the Required Proxy Statement to stockholders as promptly as practicable following sign off from the SEC on such Required Proxy Statement, or no later than the 20th day after such preliminary Proxy Statement is filed with the SEC, in the event the SEC does not notify the Company of its intent to review such Required Proxy Statement.
• Hold a shareholders meeting to seek shareholder approval for the issuance of the Conversion Shares and Warrant Shares promptly after the SEC has confirmed that it has no comments on such Required Proxy Statement.

Key Dates

Keywords

annual meeting, proxy statement, stockholders, directors, executive compensation, incentive plan, M&K CPAs, Series B Convertible Preferred Stock, warrants, Nasdaq Listing Rules, corporate governance, 180 Life Sciences